ARO Online

ARO-Studien: Publikationen (Stand 10.01.2025)

Analkarzinom

  1. Grabenbauer GG, Panzer M, Hultenschmidt B, Doker R, Huber K, Kuhne-Velte HJ, Hutter M, Ruhl U, Budach V, Wendt T et al: [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 1994, 170(7):391-399.
  2. Martin D, Balermpas P, Gollrad J, Weiss C, Valentini C, Stuschke M, Schafer H, Henckenberens C, Debus J, Krug D et al: RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol 2020, 23:43-49.

Glioblastom

  1. Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Gotz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG et al: Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC cancer 2016, 16(1):769.
  2. Straube C, Scherb H, Gempt J, Kirschke J, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE: Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial). BMC cancer 2018, 18(1):15.
  3. Bodensohn R, Fleischmann DF, Maier SH, Anagnostatou V, Garny S, Nitschmann A, et al. Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12). Clin Transl Radiat Oncol. 2024;45:100706.
  4. Maier SH, Schonecker S, Anagnostatou V, Garny S, Nitschmann A, Fleischmann DF, et al. Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06). Clin Transl Radiat Oncol. 2024;47:100790.

Hodentumore

  1. Gobel U, Bamberg M, Calaminus G, Jurgens H, Pelzer V, Simon WE, Terruhn V, Wolf A, Mecke H, Harms D: [Dysgerminomas. Clinical aspects, therapy and prognosis with reference to the cooperative therapy study MAIKEI 83/86 for non-testicular germ cell tumors of the Society of Pediatric Oncology]. Geburtshilfe Frauenheilkd 1989, 49(8):737-742.
  2. Gobel U, Bamberg M, Haas RJ, Bokkerink JP, Bramswig G, Calaminus G, Engert J, Gadner H, Havers W, Janka-Schaub GE et al: [Non-testicular germ cell tumors: analysis of the therapy study MAKEI 83/86 anc changes in the protocol for the follow-up study]. Klin Padiatr 1989, 201(4):247-260.
  3. Gobel U, Bamberg M, Engert J, Gnekow AK, Haas HJ, Jurgens H, Kuhl J, Lenard HG, Lumenta C, Niethammer D et al: [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study]. Klin Padiatr 1991, 203(4):236-245.
  4. Gobel U, Calaminus G, Teske C, Bamberg M, Bokkerink JP, Haas RJ, Holschneider AM, Janka-Schaub G, Jurgens H, Mittler U et al: [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89]. Klin Padiatr 1993, 205(4):231-240.
  5. Schmidberger H, Bamberg M: [Treatment options in early-stage testicular seminoma. Review of the literature with initial results of a prospective multicenter study on radiotherapy of clinical-stage I, IIA and IIB seminomas]. Strahlenther Onkol 1995, 171(3):125-139.
  6. Schmidberger H, Bamberg M, Meisner C, Classen J, Winkler C, Hartmann M, Templin R, Wiegel T, Dornoff W, Ross D et al: Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997, 39(2):321-326.
  7. Bamberg M, Schmidberger H, Meisner C, Classen J, Souchon R, Weinknecht S, Schorcht J, Walter F, Engenhart-Cabillic R, Schulz U et al: Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 1999, 83(6):823-827.
  8. Classen J, Souchon R, Hehr T, Bamberg M: Radiotherapy for early stages testicular seminoma: patterns of care study in Germany. Radiother Oncol 2002, 63(2):179-186.
  9. Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M, Loy V, German Testicular Cancer Study G: Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 2003, 88(6):828-831.
  10. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Kohrmann KU, Bamberg M: Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003, 21(6):1101-1106.
  11. Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R, Weissbach L, Budach V, Alberti W, Bamberg M et al: Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 2004, 90(12):2305-2311.
  12. Clasen J, Schmidberger H, Souchon R, Weissbach L, Hartmann M, Hartmann JT, Hehr T, Bamberg M: What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients. Strahlenther Onkol 2009, 185(6):349-354.

Kopf-Hals-Tumore

  1. Volling P, Staar S, Achterrath W, Muller RP: Phase I/II study of simultaneous carboplatin and radiotherapy in unresectable squamous cell carcinoma of the head and neck. Seminars in oncology 1992, 19(1 Suppl 2):66-71.
  2. Dinges S, Budach V, Stuschke M, Budach W, Boehmer D, Schrader M, Jahnke K, Sack H: Chemo-radiotherapy for locally advanced head and neck cancer--long-term results of a phase II trial. European journal of cancer 1997, 33(7):1152-1155.
  3. Hoffmann W, Belka C, Schmidberger H, Budach W, Bochtler H, Hess CF, Bamberg M: Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial. International journal of radiation oncology, biology, physics 1997, 38(4):691-696.
  4. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998, 16(4):1318-1324.
  5. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000, 18(19):3339-3345.
  6. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. International journal of radiation oncology, biology, physics 2001, 50(5):1161-1171.
  7. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1255-1260.
  8. Ernst-Stecken A, Grabenbauer G, Iro H, Plasswilm L, Sauer R: Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2004, 180(12):805-810.
  9. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T et al: Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005, 23(6):1125-1135.
  10. Hehr T, Classen J, Belka C, Welz S, Schafer J, Koitschev A, Bamberg M, Budach W: Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. International journal of radiation oncology, biology, physics 2005, 61(5):1423-1431.
  11. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V: Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. International journal of radiation oncology, biology, physics 2005, 63(4):985-990.
  12. Kuhnt T, Becker A, Bloching M, Schubert J, Klautke G, Fietkau R, Dunst J: Phase II trial of a simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated-accelerated radiotherapy in locally advanced head and neck tumors. Medical oncology 2006, 23(3):325-333.
  13. Semrau R, Mueller RP, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O, Kocher M, Eich HT, Dietz A, Flentje M et al: Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. International journal of radiation oncology, biology, physics 2006, 64(5):1308-1316.
  14. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J: Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology 2010, 21(11):2284-2289.
  15. Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L, Salzwimmer M, Lizambri R, Emmerson L, Chen MG et al: Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, 29(20):2815-2820.
  16. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J, Baumann M: Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012, 105(1):21-28.
  17. Budach V, Becker ET, Boehmer D, Badakhshi H, Jahn U, Wernecke KD, Stromberger C: Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2014, 190(3):250-255.
  18. Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P: Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. International journal of radiation oncology, biology, physics 2015, 91(5):916-924.
  19. Ghadjar P, Pottgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F et al: Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94). Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2016, 192(8):552-560.
  20. Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Johrens K, Weichert W, Linge A, Lohaus F, Krause M et al: Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. European journal of cancer 2016, 57:78-86.
  21. Hess AK, Muer A, Mairinger FD, Weichert W, Stenzinger A, Hummel M, Budach V, Tinhofer I: MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. European journal of cancer 2017, 77:3-12.
  22. Hess AK, Johrens K, Zakarneh A, Balermpas P, Von Der Grun J, Rodel C, Weichert W, Hummel M, Keilholz U, Budach V et al: Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. Oncoimmunology 2019, 8(8):1614858.
  23. Pigorsch SU, Kampfer S, Oechsner M, Mayinger MC, Mozes P, Devecka M, Kessel KK, Combs SE, Wilkens JJ: Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study. Radiat Oncol 2020, 15(1):253.
  24. Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, Rodel C, Hautmann MG, Kolbl O, Salay A et al: Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. Radiother Oncol 2020, 144:209-217.
  25. Roesch J, Oertel M, Wegen S, Trommer M, Schleifenbaum J, Hering D, et al. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis. Radiother Oncol. 2023;181:109380.
  26. Hecht M, Frey B, Gaipl US, Tianyu X, Eckstein M, Donaubauer AJ, et al. Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial. Neoplasia. 2024;49:100953.

Lebensqualität und PRO

  1. Hauth F, Gehler B, Niess AM, Fischer K, Toepell A, Heinrich V, Roesel I, Peter A, Renovanz M, Hartkopf A et al: An Activity Tracker-Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials). JMIR Res Protoc 2021, 10(9):e28524.
  2. Fabian A, Domschikowski J, Letsch A, Schmalz C, Freitag-Wolf S, Dunst J, Krug D: Clinical endpoints in trials of palliative radiotherapy: A systematic meta-research analysis. Radiother Oncol 2022, 174:123-131.
  3. Fabian A, Domschikowski J, Letsch A, Schmalz C, Freitag-Wolf S, Dunst J, Krug D: Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy: A Systematic Review. JAMA Netw Open 2022, 5(9):e2231930.
  4. Fabian A, Ruhle A, Domschikowski J, Trommer M, Wegen S, Becker JN, et al. Financial toxicity in cancer patients undergoing radiotherapy in a universal health care system - A prospective multicenter study of 1075 patients. Radiother Oncol. 2023;183:109604.

Lungenkarzinom

  1. Fleckenstein J, Hellwig D, Kremp S, Grgic A, Groschel A, Kirsch CM, Nestle U, Rube C: F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. International journal of radiation oncology, biology, physics 2011, 81(4):e283-289.
  2. Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, Kepka L, Marschke G, Feltl D, Fietkau R et al: Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011, 100(1):76-85.
  3. Soliman M, Yaromina A, Appold S, Zips D, Reiffenstuhl C, Schreiber A, Thames HD, Krause M, Baumann M: GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2013, 106(3):299-304.
  4. Eberhardt WE, Pottgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M et al: Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015, 33(35):4194-4201.
  5. Pottgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, Heinzelmann F, Cordes S, Schuler MH, Welter S et al: Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016, 34(21):2526-2533.
  6. Butof R, Simon M, Lock S, Troost EGC, Appold S, Krause M, Baumann M: PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial. Trials 2017, 18(1):608.
  7. Hechtner M, Krause M, Konig J, Appold S, Hornemann B, Singer S, Baumann M: Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2018, 126(2):283-290.
  8. Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K et al: Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. European journal of nuclear medicine and molecular imaging 2019, 46(7):1439-1447.
  9. Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Kusters A, Tosch M, Hehr T, Eschmann SM, Bultel YP et al: Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol 2020, 21(4):581-592.
  10. Gkika E, Lenz S, Schimek-Jasch T, Waller CF, Kremp S, Schaefer-Schuler A, Mix M, Kusters A, Tosch M, Hehr T et al: Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan Trial. Cancers (Basel) 2020, 12(11).
  11. Gkika E, Schimek-Jasch T, Kremp S, Lenz S, Stockinger M, Schaefer-Schuler A, Mix M, Kusters A, Tosch M, Hehr T et al: Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. Radiother Oncol 2021, 163:32-38.
  12. Carles M, Fechter T, Radicioni G, Schimek-Jasch T, Adebahr S, Zamboglou C, Nicolay NH, Marti-Bonmati L, Nestle U, Grosu AL et al: FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy. Cancers (Basel) 2021, 13(4).
  13. Regnery S, Ristau J, Weykamp F, Hoegen P, Sprengel SD, Paul KM, Buchele C, Kluter S, Rippke C, Renkamp CK et al: Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3). Radiat Oncol 2022, 17(1):102.
  14. Maurer M, Kasmann L, Fleischmann DF, Oertel M, Jazmati D, Medenwald D, Young DTG: PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study. Radiat Oncol 2022, 17(1):29.
  15. Kasmann L, Taugner J, Eze C, Nieto A, Pelikan C, Florsch B, Kenndoff S, Hofer TP, Nossner E, Schulz C et al: Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study. Transl Lung Cancer Res 2022, 11(7):1503-1509.
  16. Brose A, Michalski K, Ruf J, Tosch M, Eschmann SM, Schreckenberger M, et al. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort. Cancer Imaging. 2023;23:45.
  17. Craddock M, Nestle U, Koenig J, Schimek-Jasch T, Kremp S, Lenz S, et al. Cardiac Function Modifies the Impact of Heart Base Dose on Survival: A Voxel-Wise Analysis of Patients With Lung Cancer From the PET-Plan Trial. J Thorac Oncol. 2023;18:57-66.
  18. Gkika E, Dejonckheere CS, Sahlmann J, Barth SA, Schimek-Jasch T, Adebahr S, et al. Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial. Radiother Oncol. 2024;200:110521.
  19. Brose A, Miederer I, Konig J,  Gkika E, Sahklmann J, Schimek-Jasch T, et al. Prognostic value of metabolic tumor volumen on [(18)F]FDG PET/CT in addtion to the TNM classification system of locally advanced non-small cell lung cancer. Cancer Imaging. 2024;24:171.
  20. Schulte C, Gauler T, Pottgen C, Friedel G, Kopp HG, Fischer B, et al. Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE). Int J Cancer. 2024;156:154-63.

Mammakarzinom

  1. Winzer KJ, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H, Schumacher M, German Breast Cancer Study G: Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. European journal of cancer 2010, 46(1):95-101.
  2. Dellas K, Vonthein R, Zimmer J, Dinges S, Boicev AD, Andreas P, Fischer D, Winkler C, Ziegler A, Dunst J et al: Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01). Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 2014, 190(7):646-653.
  3. Krug D, Baumann R, Krockenberger K, Vonthein R, Schreiber A, Boicev A, Wurschmidt F, Weinstrauch E, Eilf K, Andreas P et al: Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial. Strahlenther Onkol 2021, 197(1):48-55.
  4. Krug D, Vonthein R, Illen A, Olbrich D, Barkhausen J, Richter J, Klapper W, Schmalz C, Rody A, Maass N et al: Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol 2021, 28:90-96.
  5. Pfaffendorf C, Vonthein R, Krockenberger-Ziegler K, Dellas K, Schreiber A, Uhlemann D, Dinges S, Wurschmidt F, Andreas P, Weinstrauch E et al: Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials. Breast 2022, 64:136-142.

Metastasen

  1. Wiegel T, Bottke D, Kreusel KM, Schmidt S, Bornfeld N, Foerster MH, Hinkelbein W, German Cancer S: External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002, 64(1):13-18.
  2. Rades D, Segedin B, Conde-Moreno AJ, Garcia R, Perpar A, Metz M, Badakhshi H, Schreiber A, Nitsche M, Hipp P et al: Radiotherapy With 4 Gy x 5 Versus 3 Gy x 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016, 34(6):597-602.
  3. Grosu AL, Frings L, Bentsalo I, Oehlke O, Brenner F, Bilger A, Fennell JT, Rothe T, Schneider-Fuchs S, Graf E et al: Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG). BMC Cancer 2020, 20(1):532.
  4. Popp I, Rau A, Kellner E, Reisert M, Fennell JT, Rothe T, Nieder C, Urbach H, Egger K, Grosu AL et al: Hippocampus-Avoidance Whole-Brain Radiation Therapy Is Efficient in the Long-Term Preservation of Hippocampal Volume. Front Oncol 2021, 11:714709.

Pankreaskarzinom

  1. Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R: Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics 2003, 55(1):144-153.
  2. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG: Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008, 26(16):2699-2706.
  3. Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T et al: Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 2015, 191(1):7-16.
  4. Wittel UA, Lubgan D, Ghadimi M, Belyaev O, Uhl W, Bechstein WO, Grutzmann R, Hohenberger WM, Schmid A, Jacobasch L et al: Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. BMC Cancer 2019, 19(1):979.
  5. Fietkau R, Grutzmann R, Wittel UA, Croner RS, Jacobasch L, Neumann UP, Reinacher-Schick A, Imhoff D, Boeck S, Keilholz L et al: R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007+/- trial. Strahlenther Onkol 2021, 197(1):8-18.
  6. Pavic M, Niyazi M, Wilke L, Corradini S, Vornhulz M, Mansmann U, Al Tawil A, Fritsch R, Horner-Rieber J, Debus J et al: MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC). Radiat Oncol 2022, 17(1):18.

Prostatakarzinom

  1. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M et al: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009, 27(18):2924-2930.
  2. Bottke D, Golz R, Storkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T: Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. European urology 2013, 64(2):193-198.
  3. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A et al: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. European urology 2014, 66(2):243-250.
  4. Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stockle M, Rube C, Semjonow A, Wirth M, Storkel S et al: Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. International journal of radiation oncology, biology, physics 2015, 91(2):288-294.
  5. Habl G, Katayama S, Uhl M, Kessel KA, Edler L, Debus J, Herfarth K, Sterzing F: Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial. BMC cancer 2015, 15:868.
  6. Jiang P, Krockenberger K, Vonthein R, Tereszczuk J, Schreiber A, Liebau S, Huttenlocher S, Imhoff D, Balermpas P, Keller C et al: Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiation oncology 2017, 12(1):138.
  7. Ghadjar P, Aebersold DM, Albrecht C, Bohmer D, Flentje M, Ganswindt U, Hocht S, Holscher T, Muller AC, Niehoff P et al: Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 2020, 196(7):589-597.
  8. Beck M, Bohmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Hocht S, Holscher T, Muller AC, Niehoff P et al: Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer: Statement from the DEGRO working group on prostate cancer. Strahlenther Onkol 2020, 196(2):109-116.
  9. Ghadjar P, Aebersold DM, Albrecht C, Bohmer D, Flentje M, Ganswindt U, Hocht S, Holscher T, Muller AC, Niehoff P et al: Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 2020, 196(7):589-597.
  10. Pinkawa M, Aebersold DM, Bohmer D, Flentje M, Ghadjar P, Schmidt-Hegemann NS, Hocht S, Holscher T, Muller AC, Niehoff P et al: Radiotherapy in nodal oligorecurrent prostate cancer. Strahlenther Onkol 2021, 197(7):575-580.
  11. Ristau J, Horner-Rieber J, Buchele C, Kluter S, Jakel C, Baumann L, Andratschke N, Garcia Schuler H, Guckenberger M, Li M et al: Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial. Radiat Oncol 2022, 17(1):75.
  12. Zamboglou C, Spohn SKB, Ruf J, Benndorf M, Gainey M, Kamps M, Jilg C, Gratzke C, Adebahr S, Schmidtmayer-Zamboglou B et al: PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). Int J Radiat Oncol Biol Phys 2022, 113(5):1025-1035.
  13. Shelan M, Aebersold DM, Albrecht C, Bohmer D, Flentje M, Ganswindt U, Hocht S, Holscher T, Muller AC, Niehoff P et al: Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO). Strahlenther Onkol 2021, 197(11):993-1000.
  14. Krug D, Imhoff D, Haidenberger A, Hessler N, Schafer J, Huttenlocher S, et al. Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial. Strahlenther Onkol. 2023;199:565-73.

Rektumkarzinom

  1. Sauer R, Fietkau R, Wittekind C, Martus P, Rodel C, Hohenberger W, Jatzko G, Sabitzer H, Karstens JH, Becker H et al: Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). Strahlenther Onkol 2001, 177(4):173-181.
  2. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003, 21(16):3098-3104.
  3. Sauer R, Fietkau R, Wittekind C, Rodel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH, Becker H et al: Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis 2003, 5(5):406-415.
  4. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740.
  5. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23(34):8688-8696.
  6. Fietkau R, Rodel C, Hohenberger W, Raab R, Hess C, Liersch T, Becker H, Wittekind C, Hutter M, Hager E et al: Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 2007, 67(4):1008-1019.
  7. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Furst A, Schwella N, Bieker M, Hellmich G et al: Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007, 25(1):110-117.
  8. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S et al: Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008, 72(1):99-107.
  9. Rodel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F, Hinke A, Hohenberger W et al: Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008, 70(4):1081-1086.
  10. Kalata P, Martus P, Zettl H, Rodel C, Hohenberger W, Raab R, Becker H, Liersch T, Wittekind C, Sauer R et al: Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry. Dis Colon Rectum 2009, 52(3):425-437.
  11. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rodel C: Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010, 78(2):472-478.
  12. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR et al: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13(7):679-687.
  13. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012, 30(16):1926-1933.
  14. Dellas K, Hohler T, Reese T, Wurschmidt F, Engel E, Rodel C, Wagner W, Richter M, Arnold D, Dunst J: Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol 2013, 8:90.
  15. Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau T, Dellas K, Kitz J, Rodel F, Sauer R et al: Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. Int J Radiat Oncol Biol Phys 2013, 87(5):992-999.
  16. Wolff HA, Conradi LC, Beissbarth T, Leha A, Hohenberger W, Merkel S, Fietkau R, Raab HR, Tschmelitsch J, Hess CF et al: Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol 2013, 108(1):48-54.
  17. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S et al: Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014, 32(15):1554-1562.
  18. Fokas E, Liersch T, Fietkau R, Hohenberger W, Hess C, Becker H, Sauer R, Wittekind C, Rodel C: Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon? Cancer 2015, 121(11):1724-1727.
  19. Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M et al: Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015, 16(8):979-989.
  20. Sprenger T, Rothe H, Conradi LC, Beissbarth T, Kauffels A, Kitz J, Homayounfar K, Wolff H, Strobel P, Ghadimi M et al: Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup. Dis Colon Rectum 2016, 59(5):377-385.
  21. Fokas E, Strobel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, Hartmann A, Kaufmann M, Sauer R, Graeven U et al: Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. J Natl Cancer Inst 2017, 109(12).
  22. Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grutzmann R, Ghadimi M, Liersch T, Strobel P, Grabenbauer GG, Graeven U et al: Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol 2018, 29(7):1521-1527.
  23. Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, Fietkau R, Hohenberger W, Ghadimi M, Liersch T et al: Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Ann Oncol 2018, 29(8):1793-1799.
  24. Kitz J*, Fokas E*, Beissbarth T, Strobel P, Wittekind C, Hartmann A, Ruschoff J, Papadopoulos T, Rosler E, Ortloff-Kittredge P et al: Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Surg 2018, 153(8):e181607.
  25. Sprenger T, Beissbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab HR et al: Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. Br J Surg 2018, 105(11):1510-1518.
  26. von den Grun JM, Hartmann A, Fietkau R, Ghadimi M, Liersch T, Hohenberger W, Weitz J, Sauer R, Wittekind C, Strobel P et al: Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. Radiother Oncol 2018, 128(3):557-563.
  27. Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grun J, Grutzmann R, Liersch T, Strobel P et al: Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019.
  28. Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL et al: Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019, 37(34):3212-3222.
  29. Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rodel C, Fokas E: Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020, 6(9):1416-1421.
  30. Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rodel C, Fokas E: Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. JAMA Oncol 2020, 6(2):294-296.
  31. Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P et al: Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020, 21(5):e252-e264.
  32. Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, Hohenberger W, Arnold D, Hofheinz RD et al: Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. Eur J Cancer 2021, 144:281-290.
  33. Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Fleischmann M, Fokas E, Rodel C: Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. Radiother Oncol 2021, 164:223-231.
  34. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL et al: Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol 2021:e215445.
  35. Fleischmann M, Diefenhardt M, Nicolas AM, Rodel F, Ghadimi M, Hofheinz RD, Greten FR, Rodel C, Fokas E, German Rectal Cancer Study G: ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. Clin Transl Radiat Oncol 2022, 34:99-106.
  36. Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso P, Bechstein WO, Hildebrandt G, Ghadimi M, Hofheinz RD, Rodel C et al: Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. Cancers (Basel) 2022, 14(15).
  37. Diefenhardt M, Martin D, Ludmir EB, Fleischmann M, Hofheinz RD, Ghadimi M, Kosmala R, Polat B, Friede T, Minsky BD et al: Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial. Cancers (Basel) 2022, 14(18).
  38. Diefenhardt M, Fleischmann M, Martin D, Hofheinz RD, Piso P, Germer CT, Hambsch P, Grutzmann R, Kirste S, Schlenska-Lange A et al: Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) A comparison between two multicenter randomized phase II/III trials. Radiother Oncol 2022:109455.
  39. Zimmermann M, Richter A, Weick S, Exner F, Mantel F, Diefenhardt M, Fokas E, Kosmala R, Flentje M, Polat B: Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center. Sci Rep 2022, 12(1):21263.
  40. Wurschi GW, Gullmar D, Gassler N, Clement J, Kesselmeier M, Muller-Wurschi JJ, et al. Planning adaptive treatment by longitudinal response assessment implementing MR imaging, liquid biopsy and analysis of microenvironment during neoadjuvant treatment of rectal cancer (PRIMO). Medicine (Baltimore). 2023;102:e33575.
  41. Diefenhardt M, Fleischmann M, Martin D, Hofheinz RD, Piso P, Germer CT, Rödel C, Fokas E: Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials. Radiother Oncol. 2023;179:109455.
  42. Diefenhardt M, Martin D, Fleischmann M, Hofheinz RD, Ghadimi M, Rodel C, Fokas E. Overall Survival After Treatment Failure Among Patients With Rectal Cancer. JAMA Netw Open. 2023;6:e2340256.
  43. Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer. 2024;210:114291.
  44. Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, et al. mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). ESMO Open. 2024;9:103703.
  45. Diefenhardt M, Martin D, Hofheinz RD, Ghadimi M, Fokas E, Rodel C, Fleischmann M. Persistent Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Rectal Cancer. JAMA Netw Open. 2024;7:e2432927.
  46. Diefenhardt M, Martin D, Fleischmann M, Hofheinz RD, Ghadimi M, Rodel C, Fokas E. Tumor Response and Its Impact on Treatment Failure in Rectal Cancer: Does Intensity of Neoadjuvant Treatment Matter? Cancers (Basel). 2024;16.

Zervixkarzinom

  1. Marnitz S, Martus P, Kohler C, Stromberger C, Asse E, Mallmann P, Schmidberger H, Affonso Junior RJ, Nunes JS, Sehouli J et al: Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. International journal of radiation oncology, biology, physics 2016, 94(2):243-253.
  2. Marnitz S, Tsunoda AT, Martus P, Vieira M, Affonso Junior RJ, Nunes J, Budach V, Hertel H, Mustea A, Sehouli J et al: Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study. Int J Gynecol Cancer 2020, 30(12):1855-1861.